Close Menu

NEW YORK (GenomeWeb) – Myriad Genetics has submitted BRACAnalysis CDx for review by Japan's Pharmaceutical Medical Devices Agency and for marketing approval by its Ministry of Health, Labor and Welfare.

If approved, the companion diagnostic can be used to identify which HER2-negative, metastatic breast cancer patients have germline mutations in BRCA1 and BRCA2 genes and are likely to respond to AstraZeneca's Lynparza (olaparib).

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Mar
21
Sponsored by
Loop Genomics

This webinar provides a comparison of next-generation sequencing (NGS) approaches for human transcriptome sequencing, including short-read Illumina sequencing and synthetic long-read sequencing technology.

Mar
27
Sponsored by
Swift Biosciences

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost. 

Apr
09
Sponsored by
Sophia Genetics

This webinar will present the utility of a personalized in silico analytical approach for the routine clinical diagnosis of channelopathies and cardiomyopathies. 

Apr
11
Sponsored by
Bionano Genomics

This webinar will review a recent study that applied whole-genome sequencing and optical genome mapping to identify a large number of previously undetected somatic structural variants in leukemia samples.